Cor Vasa 2010, 52(4):238-243 | DOI: 10.33678/cor.2010.059

Correlation between the SYNTAX Score and serum matrix metalloproteinase-3 levels in patients with chronic coronary heart disease

Martin Gřiva1,*, Robert Náplava1, Milada Špendlíková2, Jiří Jarkovský3, Ota Hlinomaz4, Čestmír Číhalík1
1 Interní klinika, Krajská nemocnice T. Bati, a. s., Zlín
2 Imunologická laboratoř, Krajská nemocnice T. Bati, a. s., Zlín
3 Institut biostatistiky a analýz, Lékařská a Přírodovědecká fakulta Masarykovy univerzity, Brno
4 I. interní kardioangiologická klinika, Fakultní nemocnice u sv. Anny, Brno, Česká republika

Aim: The SYNTAX Score is designed to describe the extent of coronary artery involvement by atherosclerosis. Among other things, matrix metalloproteinases play an important role in the pathogenesis of vascular diseases such as atherosclerosis, plaque rupture, and aneurysm. The study was conducted to determine whether or not there is a correlation between matrix metalloproteinase-3 (MMP-3) levels and the SYNTAX Score in patients with chronic coronary heart disease.

Methods: A total of 128 randomly selected patients with chronic coronary heart disease (CHD) (75% of men, 69% of individuals with diabetes; the exclusion criteria included troponin I positivity, heart failure, renal insufficiency, systemic and inflammatory conditions) had blood samples obtained to determine MMP-3 levels using ELISA. Subsequently, the patients had coronary angiography and their Syntax Score was determined.

Results: MMP-3 levels were significantly higher in patients with diabetes, 37.0 μg/l (13.7-82.5), compared with individuals without diabetes, 25.8 μg/l (11.9-82.8 μg/l); p = 0.044. MMP-3 levels were significantly higher in males, 42.1 μg/l (15.7-85.2 μg/l), than in females, 21,9 μg/l (11,3-44,8 μg/l); p < 0.001. Using Spearman's rank correlation coefficient, a significant correlation was demonstrated between the SYNTAX Score and MMP-3 levels in the whole group of patients as well as in subgroups of individuals with and without diabetes.

Conclusion: In patients with chronic CHD, MMP-3 levels correlate with the extent of coronary artery involvement regardless of the presence or absence of diabetes mellitus.

Keywords: Atherosclerosis; SYNTAX Score; Matrix metalloproteinase-3

Published: April 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gřiva M, Náplava R, Špendlíková M, Jarkovský J, Hlinomaz O, Číhalík Č. Correlation between the SYNTAX Score and serum matrix metalloproteinase-3 levels in patients with chronic coronary heart disease. Cor Vasa. 2010;52(4):238-243. doi: 10.33678/cor.2010.059.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. European Detailed Mortality Database. World Health Organization Regional Office for Europe, 2009.
    2. Staněk V, Bultas J, Škvařilová M, Aschermann M. Chronická ischemická choroba srdeční. In: Aschermann M (ed.) Kardiologie. 1. vydání. Praha: Galén, 2004:596-650.
    3. Veselka J, Adla T. Deset důvodů, proč se kardiolog musí zajímat o CT vyšetření srdce. Cor Vasa 2009;51:9-11. Go to original source...
    4. Serruys PW, Morice MC, Kappetein AP, et al; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-972. Go to original source... Go to PubMed...
    5. Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007;82:1375-1381. Go to original source... Go to PubMed...
    6. Yu Y, Koike T, Kitajima S, et al. Temporal and quantitative analysis of expression of metalloproteinases (MMPs) and their endogenous inhibitors in atherosclerotic lesions. Histol Histopathol 2008;23:1503-1516. Go to PubMed...
    7. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroInterv 2005;1:219-227.
    8. Škrha J. Od rizik po komplikace - biochemie a patofyziologie. In: Perušičová J (ed.) Co je nového na cestě od diabezity po kardiabetes. Praha: GEUM, 2006:81-93.
    9. Valgimigli M, Serruys PW, Tsuchida K, et al. Cyphering the complexity of coronary artery disease using the SYNTAX Score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. Am J Cardiol 2007;99:1072-1081. Go to original source... Go to PubMed...
    10. van Gaal W, Ponnuthurai F, Selvanayagam J, et al. The SYNTAX Score predicts peri-procedural myocardial necrosis during percutaneous coronary intervention. Int J Cardiol 2009;135:60-65. Go to original source... Go to PubMed...
    11. Humphries SE, Martin S, Cooper J, Miller G. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary hweart disease in healthy men. Ann Hum Genet 2002;66: 343-352. Go to original source...
    12. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653. Go to original source... Go to PubMed...
    13. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589. Go to original source... Go to PubMed...
    14. McQueen MJ, Hawken S, Wang X, et al.; INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008;372:224-233. Go to original source... Go to PubMed...
    15. Panayiotou A, Griffin M, Georgiou N, et al. ApoB/ApoA1 ratio and subclinical atherosclerosis. Int Angiol 2008;27:74-80. Go to PubMed...
    16. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Circ Res 2003;92:827-839. Go to original source... Go to PubMed...
    17. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure, and function. Biochim Biophys Acta 2000; 1477:267-283. Go to original source... Go to PubMed...
    18. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251-262. Go to original source...
    19. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001;89:201-210. Go to original source... Go to PubMed...
    20. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002;90:520-530. Go to original source... Go to PubMed...
    21. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-3727. Go to original source... Go to PubMed...
    22. Rouis M, Adamy C, Duverger N, et al. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 1999;100:533-540. Go to original source... Go to PubMed...
    23. Allaire E, Forough R, Clowes M, et al. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest 1998;102:1413-1420. Go to original source... Go to PubMed...
    24. Siminelakis S, Kotsanti A, Kolaitis N, et al. Circulating matrix metalloproteinase 3 due to myocardial ischemia. Heart Surg Forum 2009;12: E230-E234. Go to original source... Go to PubMed...
    25. Samnegård A, Silveira A, Tornvall P, et al. Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med 2006;259:530-536. Go to original source... Go to PubMed...
    26. Kelly D, Khan S, Cockerill G, et al. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 2008;10:133-139. Go to original source... Go to PubMed...
    27. Ohtsuka T, Nishimura K, Kurata A, et al. Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy. J Card Fail 2007;13:752-758. Go to original source... Go to PubMed...
    28. Dogan A, Tuzun N, Turker Y, et al. Matrix metalloproteinases and inflammatory markers in coronary artery ectasia: their relationship to severity of coronary artery ectasia. Coron Artery Dis 2008;19:559-563. Go to original source... Go to PubMed...
    29. Carrell TW, Burnand KG, Wells GM, et al. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 2002;105: 477-482. Go to original source... Go to PubMed...
    30. Chen QJ, Lu L, Peng WH, et al. Polymorphisms of MMP-3 and TIMP-4 genes affect angiographic coronary plaque progression in non-diabetic and type 2 diabetic patients. Clin Chim Acta 2009;405:97-103. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes